MiMedx Group (NASDAQ:MDXG) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of MiMedx Group (NASDAQ:MDXG) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Several other equities research analysts have also commented on the stock. Raymond James Financial set a $8.00 target price on shares of MiMedx Group in a research report on Monday, August 17th. Weiss Ratings reiterated a “sell (d)” rating on shares of MiMedx Group in a report on Thursday, August 13th. Seaport Research Partners cut shares of MiMedx Group to a “neutral” rating in a research note on Monday, August 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $8.00 price objective on shares of MiMedx Group in a research note on Monday, August 17th. Finally, Craig Hallum boosted their price objective on shares of MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.57.

MiMedx Group Stock Down 0.2%

MDXG opened at $4.50 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The business has a 50 day simple moving average of $4.18 and a 200-day simple moving average of $4.09. The stock has a market capitalization of $655.92 million, a P/E ratio of 112.53 and a beta of 1.45. MiMedx Group has a 12 month low of $3.03 and a 12 month high of $7.97.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The firm had revenue of $64.36 million for the quarter, compared to the consensus estimate of $63.46 million. On average, equities analysts anticipate that MiMedx Group will post -0.1 earnings per share for the current fiscal year.

Institutional Trading of MiMedx Group

Several large investors have recently bought and sold shares of MDXG. Punch & Associates Investment Management Inc. acquired a new position in shares of MiMedx Group in the second quarter worth $7,924,000. Paradigm Capital Management Inc. NY purchased a new stake in shares of MiMedx Group in the second quarter valued at $15,681,000. Renaissance Technologies LLC boosted its stake in shares of MiMedx Group by 22.4% during the first quarter. Renaissance Technologies LLC now owns 3,019,871 shares of the company’s stock valued at $11,928,000 after acquiring an additional 552,806 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new stake in shares of MiMedx Group during the fourth quarter valued at $7,134,000. Finally, Pillsbury Lake Capital LLC purchased a new stake in MiMedx Group during the 2nd quarter worth about $828,670. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.